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Biomolecule–polymer hybrid compartments:
combining the best of both worlds
Claire E. Meyer,† Sarah-Luise Abram, † Ioana Craciun and Cornelia G. Palivan *
Compartmentalization is a fundamental principle in biology that is needed for the temporal and spatial
separation of chemically incompatible reactions and biomolecules. Nano- or micro-sized compartments
made of synthetic polymers are used to mimick this principle. The self-assembly of these polymers into
vesicular objects is highly compatible with the integration of biomolecules, either into the lumen, the
membrane or onto the surface of the vesicles. Thus, a great variety of biohybrid nano- and microscaled
compartments has been developed exploiting the specific function and properties of targeting peptides,
antibodies, enzymes, nucleic acids or lipids. Such biohybrid compartments have moved from simple
systems encapsulating e.g. a model protein into complex multicompartmentalized structures that are
able to combine the activity of different biomolecular cargos getting closer to the realization of artifical
organelles or cells. Encapsulation of medically relevant cargos combined with careful design of
the polymeric scaffold and specific surface functionalization have led to a significant progress in
therapeutical applications such as targeted drug delivery or enzyme replacement therapy.
Introduction
The most prominent example of a biological compartment is a
cell, as it encloses an aqueous volume within its thin phospho-
lipidic membrane to form a micrometer-sized vesicle. The
compartmentalization of chemical reactions is a fundamental
characteristic of cellular life, which has been the centre of
numerous studies aiming to mimic some of the biological
functions. Liposomes, spherical vesicles made of phospholipids,
have been the spearhead for the development of micrometre-sized
artificial vesicles used as protocells. Beyond that, their nanometre-
sized analogues have gained particular interest in drug delivery as
therapeutic payloads can be encapsulated inside the vesicles’
lumen. At the same time, stealth or targeting agents can be
anchored in their membrane or attached to the surface of the
vesicles. Later, the formation of nano- or micro-sized vesicles was
also demonstrated with synthetic polymers.1–3 These polymeric
vesicles position themselves as an attractive alternative as they
demonstrate an enhanced robustness and a greater chemical
versatility while, when appropriately selected, they retain the
liposomes’ typical softness. The progress in polymer chemistry
gave access to a variety of copolymers with tailored properties and
excellent biocompatibility that can compete with the intrinsic
biocompatibility and biodegradability of natural polymers. The
precise chemical tuning (e.g. length, charge, or responsiveness)
and the possibility of easy functionalization with reactive moieties
for bioconjugation makes synthetic copolymers great building
blocks for biohybrid compartments. Such biohybrid compart-
ments integrate biomolecules for their specific functionality into
their polymeric scaffold and thus inherit the advantages of
both biological and synthetic systems. The different biological
components can be (I) attached to the compartment’s surface,
(II) encapsulated inside the cavity or (III) integrated into its
membrane (Fig. 1). Thereby, different classes of biomolecules
can be exploited for their specific functions in different
positions of the compartment. A peptide for targeting on the
surface can for instance be combined with encapsulated siRNA
as cargo or a channel protein embedded inside the membrane
allows the access of substrates to an enzyme encapsulated in
the cavity.
In this review we explore the various approaches in which
biomolecules can be combined with synthetic polymeric systems
to obtain superior biohybrid materials. Specifically, we highlight
the recent advances in the development of nano- and micro-
sized polymeric compartments combined with peptides, anti-
bodies, nucleic acids, sugars, proteins/enzymes or lipids as
biological components. We omit assemblies of natural poly-
mers like chitosan or alginate or polymeric biomolecules like
peptides or DNA. We will first cover nano-sized assemblies,
then compartments in the micrometre size range and finally
the combination of both in multicompartment systems.
An overview regarding the used polymers for capsules and
vesicles, their properties and the methods for self-assembly
and capsule preparation will be given beforehand.
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Synthetic nano/micro-sized polymer
compartments
Self-assembly and compartment formation
In general, there are two ways to prepare nano-/micro-sized
compartments from synthetic polymers: either their intrinsic
properties allow the self-assembly in aqueous solution into
hollow structures or the cavity is obtained by their deposition
on a sacrificial template particle that is dissolved afterwards to
result in a hollow polymeric capsule. Self-assembly can be
achieved on one hand by hydrophobic/hydrophilic interactions
using amphiphilic molecules such as synthetic block-
copolymers or peptides. At certain ratios of the hydrophilic to
hydrophobic blocks they form ordered vesicular structures in
aqueous solution that are called (in analogy to their lipid
counterparts) polymersomes at the nanoscale and giant uni-
lamellar vesicles (GUVs) at the microscale. On the other hand,
ionic/electrostatic interactions of oppositely charged polymers
Fig. 1 Schematic representation of (A) the different types of biomolecules and their possible locations within the polymeric assemblies and (B) the
different types of hybrid polymer/biomolecule compartments (polymersomes, PICsomes, LbL capsules), showing their diversity in terms of size and
arrangement, modified with permission from ref. 65.
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(polyelectrolytes) can also result in the formation of nano- and
micro-sized vesicles referred to as PICsomes (Poly Ion Complex).
Amphiphilic block-copolymers
Amphiphilic block-copolymers can consist of two (AB), three
(ABA/ABC) or even more (ABABAB. . .) blocks with one being
hydrophilic (A and C) and the other one being hydrophobic (B).
Either the two polymeric blocks are prepared separately and
connected afterwards with a covalent bond (e.g. by a click
reaction) or the first block is functionalized after its poly-
merisation to become a ‘‘macroinitiator’’.4 The first block can
thus be extended just by addition of the second type of monomer.
Commonly used polymerizations include controlled radical
polymerisation (e.g. ATRP, RAFT) and ionic (ring-opening)
polymerisations and their combinations. More details can be
found in the specific literature on block-copolymer synthesis.5
Popular hydrophilic blocks include PMOXA, PEG, PGMA, PAA
and PIAT; examples for hydrophobic blocks comprise PDMS,
PS, PMA, PB, PCL, PHPMA, or PNIPAM. The Tables 1 and 2
provide all polymers used for the preparation of the biohybrid
compartments referenced in this review. In case one of the used
blocks responds to a certain chemical or physical stimulus, the
vesicles present a high potential for applications in triggered
drug release or the field of sensors. Thus, the properties of the
vesicles can be fine-tuned by a careful selection of character-
istics of the hydrophobic and hydrophilic polymer blocks. The
membrane thickness can for instance be varied in the range of
5–30 nm depending on the molecular weight of the block-
copolymer.6 Permeability and mechanical stability are as well
influenced by the choice of the two building blocks and their
molecular weight (MW). As an example, PDMS–PMOXA poly-
mersomes are typically considered to be impermeable even for
small molecules whereas assemblies from PS–PIAT provide
semipermeable features.7
The different types of block-copolymers can organise in
different types of membranes (see Fig. 2A), e.g. an AB–BA
bilayer with the hydrophobic blocks within the membrane
and the hydrophilic ones directing to the aqueous solution
outside and inside the vesicle. Triblock copolymers can form
monolayered (ABA) structures as well as bilayers with a U type
configuration of the polymer.8 In case of immiscible hydro-
philic blocks (A and C), they can form domains within the
vesicle’s membrane.9 Moreover, a selective orientation of the
longer block towards the outside and the shorter one towards
the vesicle’s interior can be achieved by careful design of
the block length in ABC type copolymers.10 Such asymmetric
membranes can favour for instance the insertion of a membrane
protein with preferential orientation.
However, the self-organisation of amphiphilic block copolymers
does not always result in the desired vesicular structures, but
spherical, cylindrical, gyroidal or lamellar ones instead.4 The
ratio of the hydrophilic to hydrophobic blocks determines to
a great extend the curvature of the membrane structures
formed during self-assembly (see Fig. 2B).11–13 The f-ratio
i.e. the ratio of the hydrophilic block’s MW to the total MW
of the block-copolymer, is used to express that influence.
Vesicular structures are generally favoured at f-ratios of
35  10%11 but depend as well on the specific copolymer.14,15
Increased f-ratios lead to a higher membrane curvature and
thus towards the formation of spherical micelles. Another way
to describe the influence of the copolymer design on the
morphology of self-assembled structures is the packing para-
meter p. It is defined as p = v/aOlc with v = volume of the
hydrophobic part, aO = contact area of the head group and lc
length of the hydrophobic part.12,13
Besides the chemical composition, the MW and the disper-
sity of the block-copolymer, the self-assembly is influenced as
well by several external factors like the used solvents, the
concentration, the presence of acids, bases or salts, and the
method used for the preparation of the vesicles.12
Several techniques are used to support the self-assembly
process. Film rehydration methods expose an anhydrous
copolymer film to a rehydration solvent (usually water or an
aqueous buffer) that induces film swelling and self-assembly
into vesicular structures. The mutual diffusion between the
rehydration solvent and the polymer film dictates the for-
mation of the polymersomes: high concentration gradients
result in the formation of nano-sized vesicles while mild
diffusion conditions lead to micro-sized vesicles.12,16 If micro-
sized vesicles are desired, the rehydration can also be sup-
ported by an oscillating electric field (electroformation of
GUVs). Film rehydration does not result in homogeneous size
distributions. Nano-sized polymersomes can be extruded
through a membrane with defined nanopores in order to
narrow the size distribution to smaller sizes. In case of micro-
sized vesicles, microfluidic tools are needed to achieve homo-
genous size distributions. The copolymers are dissolved in the
oil phase of w/o/w double emulsions produced by the micro-
fluidic device. Removal of the oil phase results in the formation
of highly monodisperse GUVs. W/o/w double emulsions are
also used in emulsion centrifugation which is the phase
transfer of emulsion droplets over an interface. This method
is for instance used for the preparation of lipid–copolymer
hybrid GUVs17 and for the encapsulation of liposomes into
GUVs.18 Furthermore, the slow exposure of a copolymer
solution in an organic solvent to an aqueous environment
can induce self-assembly into polymersomes or GUVs (solvent
exchange and solvent injections methods). The copolymer
solution can be either added to water or water can be added
slowly to the organic copolymer solution. Subsequently, the
organic solvent is either removed by evaporation or by dialysis
against water. The presence of the organic solvent during self-
assembly limits the application of these methods for biohybrid
vesicles as it might harm the functionality of the biomolecular
cargo. More detailed information on the preparation methods
and their comparison are provided by other reviews.4,14,19
Polyelectrolytes
The second possibility for the self-assembly of polymers into
membranes is based on the ionic interaction of oppositely
charged polymers forming polyion complex (PIC) vesicles called
PICsomes. The two interacting polymers are not covalently
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Table 1 Overview on nano-sized biohybrid compartments sorted by their polymeric building blocks
Polymer
Location of
biomolecules Associated biomolecules Application Ref.
Polymersome
PDMS–PMOXA-based block
copolymers
(PMDS–PMOXA–PDMS,
PEO–PDMS–PMOXA)
Cavity Enzyme (SOD) Antioxidant 66
Cavity, membrane
Protein (Hb, OmpF) ROS detoxification 67
Protein (OmpF), enzyme (HRP)
Enzyme kinetic in crowded space 77
Model of pH-responsive
nanocompartment
82
83
Protein (OmpF), enzyme (penicilin
acylase)
Model for self-defending surface 71
Protein (OmpF), enzyme
(LPO, SOD)
Artificial peroxisome 70
Protein (OmpF), enzyme
(HRP or uricase)
Detoxification of uric acid 68
Protein (a-HL, PGM) Model for glycolysis completion 85
Membrane
Peptide (gA) Stimuli-responsive
nanocompartment
36
Protein (proteorhodopsin),
lipid (DOPC)
Model for protein reconstitution
study
88
Protein (Aqp Z) Model for water
treatment/drug delivery
87
Protein (Aqp) Model for sensitive bio-device 84
Membrane, Surface Peptide (fusion eGFP-peptides) Model for surface
functionalisation
60
Surface
Peptide (NLS) Targeting/delivery 55
DNA (single strands) Interconnected organelles
mimicking
37
PEG/PEO-based block copolymers
(PEG–PCL, PEG–PLA, PEG–PTMC,
PEG–PTMC–DTC, PEG–PLGA,
PEG–PGA, PEG–PDTC–TMC, PEG–PS,
PEG–PLC. PEO–PDPA–PAA,
PEO–PCMA–DEA, PEO–PDMS–PEO,
PEO–PB)
Cavity, surface
Antibody (anti-EpCAM), siRNA
Targeting/delivery
45
Peptide (cRGD, GALA),
protein (cytC)
47
Peptide (cNGQGEQc), siRNA 48
Peptide (ApoE), protein (saporin) 54
Peptide (S14G-humanin),
protein (lactoferrin)
58
Surface
Peptide (aptamer AS1411)
Targeting/drug delivery
61
Peptide (GE11) 51
Peptide (cell penetrating) 56
Peptide (Tet-1),
Protein (transferrin)
53
Peptide (iRG) 49
Protein (transferrin) 57
Peptide (iRGD) 46
Peptide (LinTT1) 50
Peptide (NLS) 52
Membrane
Peptide (MT1) Enzyme detection 78
Protein (Mb/HRP) Model for catalyst development 81
Lipid (POPC)
Model for drug delivery
100
Lipid (POPC) 99
Lipid (HSPC) 103
Protein (BR), enzyme (ATP synthase) Model for protein
reconstitution
86
Protein (Cyt bo3), lipid (POPC) 102
Lipid (DOPC) Model for artificial organelles 101
Membrane/surface
Protein (lectin), carbohydrate
(glucopyranosyl)
Anti-diabetes therapy 59
Other block copolymers
(PTMC–PGA, PEP, PMPC–PDPA,
PS–PAA, PS–PIAT, PCL, PHPMA,
PB–PS, DEGMA, PGG, PNIPAM,
PNIPAM–CMA–DEA,
DMAEMA, PEOGA–PLA)
Cavity
DNA (plasmid) Gene delivery 63DNA (plasmid)/siRNA 64
Enzyme (trypsin) Enzyme kinetic in confined
space
75
Cavity, membrane
Protein (HSA, GFP) Intracellular delivery 80
Carbohydrate (matooligosaccharide),
enzyme (b-gal)
Enzyme prodrug therapy 74
Cavity, membrane,
surface
Enzyme (GOx, CalB, HRP) Enzyme positioning in
polymersomes
73
Perspective PCCP
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 6
/2
3/
20
20
 1
0:
52
:0
9 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©the Owner Societies 2020 Phys. Chem. Chem. Phys., 2020, 22, 11197--11218 | 11201
linked together. Usually, one anionic and one cationic PEG–
poly(amino acid)-block copolymer are simply mixed in aqueous
solution and assemble into semipermeable unilamellar mem-
branes with PEG units on both sides.20 The vesicular structure
and size can be controlled by variations of the PEG content and
the concentrations used for the self-assembly. For nano-sized
PICsomes PEG–poly(amino acid)-block copolymers should be
mixed with pure poly(amino acids) in order to lower the PEG
content further.21 Mechanical stress like vortexing and changes
in pH or ionic strength can cause the reversible disassembly of
the vesicular structure or increase its permeability. PICsomes
offer a range of properties that are beneficial for applications in
medicine. The simple preparation in purely aqueous environ-
ment together with the intrinsic biocompatibility of the
poly(amino acids) are good prerequisites for the encapsulation
of active biomolecular cargos. Stability in physiological condi-
tions was achieved by crosslinking, which also allows a fine
tuning of the permeability.22
Polymeric capsules from LbL deposition
In contrast to the previously described methods, the layer-by-
layer (LbL) technique requires the use of a colloidal particle,
mostly silica or CaCO3, as a sacrificial template for the creation
of the inner cavity.23 Two polymers interacting by electrostatic
forces or hydrogen bonding are deposited alternately on the
template before it is dissolved to obtain the hollow sphere.
Thus, the size of the template particle, which can be tuned from
nano- to micrometre size, reflects the size of the capsule’s inner
cavity. Typically, PVP and PMA which interact via hydrogen
bonding at pH values below the pKa of PMA are used for this
technique. Using thiol functionalized PMASH, the stability of
these capsules can be extended to physiologically relevant pH
by crosslinking.24 The resulting pure PMA hydrogel capsules
are biodegradable, nontoxic, semipermeable and thus well
suited for biomedical applications. Depending on the used
crosslinking chemistry, also non-degradable or selectively
degradable polymer shells can be prepared.24 More recent
studies replace the labour intense LbL assembly of PMASH/
PVP capsules by polydopamine shells that are deposited on the
template in a single step.25
Physico-chemical characterization of biohybrid polymer
compartments
In order to fully exploit the potential of biohybrid polymeric
compartments their physico-chemical properties need to be
fully understood. Thus, reliable and reproducible methods
should be used to characterize their dimensions, shape, and
morphology as well as the properties of the synthetic mem-
branes such as polarity, surface charge, elasticity, thickness,
permeability and lamellarity. Additionally, the properties and
functionality of the incorporated biomolecules (e.g. enzyme
activity, selectivity of pores, specificity of antibodies) must
be shown.
Methods for size and morphology determination of biohy-
brid compartments can be roughly divided into techniques for
direct visualization, mainly microscopy, and techniques based
on the scattering of radiation. Nano-sized vesicles are often
investigated by transmission electron microscopy (TEM). Due to
the organic nature of the samples, negative staining with electron-
rich heavy metal atoms is needed to improve contrast. The
vacuum applied during TEM measurements results in deforma-
tions that can only be avoided by cryo-techniques where the
samples are rapidly plunge-frozen in liquid alkanes in order to
preserve their original morphology by embedding them in a thin
layer of vitrified ice. Thus, membrane properties like lamellarity
and bilayer thickness get accessible (Fig. 3). Besides electron
microscopy, atomic force microscopy (AFM) belongs to the
frequently applied techniques for size and topography of
Table 1 (continued )
Polymer
Location of
biomolecules Associated biomolecules Application Ref.
Membrane
Carbohydrate (glucose) Cell glycocalyx mimicking 90
Carbohydrate (pyranoside/glucoside) Model for carbohydrate–protein
interaction study
92
Carbohydrate (hyluronic acid) Bacteria detection 91
Carbohydrate (thioglucose) Drug carrier 89
Lipid (cholesterol) Drug delivery 93
Lipid (cholesterol) Drug delivery 95
Protein (cytC), enzyme (cytC oxidase) Model for artificial chloroplast 69
Lipid (HSPC/DPPC) Model for drug delivery 104
Membrane, surface
Peptide (aptamer AS1411)
Targeting/drug delivery
60
Protein (BSA), antibody
(cetuximab)
79
Surface Antibody (Trastuzumab) Targeting/imaging 44
PICsomes PEG–P(Asp), P(Asp-AP) Cavity Enzyme (ASNase) Therapeutic catalytic
nanocarrier
106
Surface Peptide (cRGD) Drug delivery, imaging 105
LbL capsules PDPA–PEG Surface Peptide (GLGYGWS) Drug delivery 107
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Table 2 Overview on micro-sized biohybrid compartments sorted by their polymeric building blocks
Polymer Location of biomolecules Associated biomolecules Application Ref.
GUVs
PMOXA–PDMS–PMOXA
block copolymers
Cavity, membrane
Peptide (melittin), enzyme (GOx) Model for biosensors,
enzyme delivery
126
Protein (OmpF), enzyme (HRP) Model for cell mimicking 128
Membrane
Peptide (gA) Stimuli-responsive
nanocompartment
36
Peptide (lasalocid, Alamethicin,
ETH5234)
Model for biomineralization
study
124
PEO-based block
copolymers
(PEO–PB, PEO–PDMS,
PEO–PI)
Cavity Enzyme (Cat) Model for payload release 130
Membrane
Lipid (DPPC, POPC) Model for delivery platform 98Lipid (DPPC, POPC, cholesterol) 96
Lipid (DPPC, POPC) Model for lipid/polymer
hybrids study
113
Lipid (DPPC) 116
Lipid (POPC) Model for cell mimicking 17
Protein (OmpF), Lipid (DPPC) Model for membrane protein
reconstitution
127
Other block copolymers
(PNIPAM, BA and P
DMS–biomolecule
conjugates)
Cavity, membrane
Protein (BSA, ferritin, Mb),
enzyme (RNApol, ALP, LPL)
Model for cell mimicking
133
Protein (BSA), DNA, enzyme
(ALP)
134
Membrane
Carbohydrate (glucose/galactose) 119
Carbohydrate (glucose) 120
PICsomes
PEG–P(Asp), P(Asp-AP) Cavity Protein (Mb) Drug delivery 129
PEG–PLG, PLL–carbohydrate
conjugate
Carbohydrate
(mannose)
Membrane/surface Model for intercellular
recognition
122
LbL capsules
PNIPAM, PDEAEMA–PBMA
Cavity
Protein (Mb), enzyme (GOx)
Synthetic biology
137
PDEAEMA–PDSM Protein (Mb) 138
Multicompartments
PMOXA–PDMS–PMOXA
block copolymers
Cavity Protein (GFP), antibody (IgG)
Model for cell mimicking
156
Cavity, membrane Protein (OmpF), enzyme (HRP,
GOx)
76
Cavity, membrane, surface Peptide (gA), enzyme (LPL),
carbohydrate (heparin)
118
PLL, PMA, PVP based
polymers
Cavity DNA (plasmid)
Model for drug delivery
145
Peptide (Cys-KP9) 24
Cavity, membrane
(inner compartment)
Enzyme (b-lac), lipid (DMPC,
DPPC)
146
Enzyme (b-lac), lipid (DOPC,
DOPS, DMPC, DPPC, DPPS)
25
Enzyme (b-lac), lipid (DOPC,
DOPS, DPPC)
Model for therapeutic artifi-
cial cell
144
Enzyme (trypsin), lipid (PC, PE) Biomedical applications 148
Enzyme (GR), peptide (KP9),
lipid (DPPC, cholesterol)
Model for drug release and
enzyme therapy
150
Enzyme (PAL), lipid (DMPC,
DPPC, PC)
Therapeutic microreactor 151
Enzyme (subtilisin), lipid (DOPC,
DOPS, DMPC, DPPC, DPPS)
Model for cell mimicking 147
Enzyme (Gox, HRP), lipid
(DMPC, DPPC)
154
Enzyme (TRP, HRP), lipid
(DMPC, DPPC)
155
Membrane Lipid (DOPC, DOPS) 149
Other polymers
(PS–PIAT, PEO–PB,
PAH, PSS)
Cavity
Enzyme (CalB, PAMO, ADH, Alc) Model for cell mimicking/
microreactor
7
Protein (HSA), enzyme (GOx, POD) Possible biomedical
applications
143
Cavity, membrane
(inner compartment)
Enzyme (TYR), lipid (DMPC,
DPPC, PC)
Therapeutic microreactor 152
Membrane
(inner compartment)
Lipid (POPC, DMPC, DPPC, PC) Model for microreactor 18
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immobilized polymeric vesicles with the advantage that the
measurements can be performed in liquid and thus provide
information about the sample characteristics in a biologically
relevant environment while still having a nanometre resolution.
Mechanical properties like Young’s modulus or bending modulus
can be derived at the same time by force spectroscopy.26,27
Larger vesicles in the micron range can be visualized easily
in their liquid environment by light/fluorescence/confocal laser
scanning microscopy. Several super-resolution techniques are
used to overcome the diffraction limit of photons to expand
fluorescence microscopy to nanoscale compartments,28,29
e.g. SIM (structured illumination microscopy),30 SMLM (single-
molecule localization microscopy) combined with sPAINT
(spectroscopic point accumulation for imaging in nanoscale
topography)31 or STORM (stochastic optical reconstruction
microscopy) combined with single molecule tracking.32
Fluorescence correlation spectroscopy (FCS) is another
fluorescence-based technique that is of high value for the
characterization of biohybrid compartments. This method
analyses the fluctuations in fluorescence intensity of a small
number of fluorescent particles/molecules within a very tiny
volume due to diffusion (e.g. Brownian motion) by using
temporal autocorrelation. Diffusion coefficients, hydrodynamic
radii and concentrations can be derived from these data, which
is especially useful to quantify and to investigate the behavior
of fluorescently labelled biomolecules within the environment of
the polymeric membranes or inside compartments (Fig. 3).33–37
Apart from direct visualization by TEM, laser light scattering
is one of the routine measurements for simultaneous size and
morphology determination of nanosized compartments. For
dynamic light scattering (DLS), the intensity fluctuations of
the scattered laser light due to the Brownian motion of the
vesicles are used to determine the hydrodynamic radius
by Stokes–Einstein relation. However, the data interpretation
for polydisperse or anisotropic samples gets difficult. Static
light scattering (SLS), usually measured at multiple angles,
gives information about the morphology by the radius of
gyration.
Similarly, the elastic scattering of neutrons (SANS) or X-rays
(SAXS) at small angles can be used to get more detailed infor-
mation about the morphology, shape and structure of polymeric
membranes and compartments, but is limited by the need of
appropriate radiation facilities.38,39
Nanoparticle tracking analysis (NTA) combines visualization
with scattering. The light scattered by single vesicles is tracked
by a CCD camera and used to calculate the vesicle concen-
tration and the hydrodynamic diameter by Stokes–Einstein
relation.40,41 Moreover, various other techniques are applied
for sorting and purification of biohybrid compartments
(e.g. flow cytometry, size exclusion chromatography (SEC),
Fig. 2 (A) Schematic representation of different membrane architectures
resulting from different copolymer structures. (B) Influence of the
copolymer’s f-ratio on the membrane curvature and the morphology of
the self-assembly.
Fig. 3 (A) Cryo transmission electron micrograph of DNA functionalized polymersome clusters showing clearly the morphology, the membrane
thickness and the gap created by the attached DNA strands. (B) Normalized fluorescence correlation spectroscopy autocorrelation curve of
polymersomes functionalized with ssDNA and the hybridized fluorescently labelled complementary strand (dark yellow, red fit) and the free fluorescently
labelled ssDNA (blue, red fit). Reprinted with permission from ref. 37. Copyright (2016) American Chemical Society.
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asymmetrical flow field-flow fractionation (AF4)). Structural
and mechanical properties of polymeric vesicles are also sub-
ject of computational studies using coarse-grained simulations
such as dissipative particle dynamics.42,43 Shape transforma-
tion, rupture, fusion, and membrane characteristics could be
simulated and used to explain experimental results. However,
the interaction or integration of biomolecules within polymer
membranes is not covered extensively by this field yet.
Nano-sized single compartment
biohybrid vesicles
Biohybrid polymersomes with surface functionalisation
Nano-sized polymer vesicles (polymersomes) position them-
selves as an attractive platform for biological applications as
they allow the encapsulation of hydrophilic compounds within
their internal cavity, the insertion of hydrophobic small mole-
cules in their membrane and the attachment of a wide variety
of compounds on their external surface.
In this way, polymersomes combined with the biomolecule
of interest have been widely exploited in medical applications,
especially for targeting applications and drug delivery. Poly-
mersomes surface-functionalized with cell specific targeting
ligands like antibodies enable to combine the robustness and
loading capacity of the polymeric compartments with the high
binding affinity of antibodies.44,45 For example, Trastuzumab,
the first monoclonal humanized antibody approved by FDA,
was chosen as a ligand to direct maghemite nanoparticle-filled
polymersomes to specific breast cancer cells in order to develop
a novel MRI contrast agent.44 However, antibodies are expen-
sive to produce, large in size and often immunogenic which
motivates the use of alternatives.
Targeting or cell penetrating peptides, less expensive and
smaller than antibodies, have been widely exploited to target
polymersomes to locations of interest within cells or living
organisms. For example, cyclic (RGD and NGQ),46–49 pH sensi-
tive fusogenic (GALA)47 and other targeting (GE11, NLS,
LinTT1, ApoE, Tet-1)50–54 peptides have been mainly used to
deliver smart polymer vehicles to specific cells or organelles
and/or to improve their tumour penetration for therapeutic or
diagnostic applications. Recently, targeting of the nuclear
interior has been achieved using polymersomes functionalized
with nuclear localization signal (peptide NLS), which position
themselves as promising nanocarriers for drug delivery to cell
nuclei.55 The most frequent approach to prepare such vesicular
peptide/polymer biohybrids consists in the preparation of
polymer compartments followed by the decoration of their
surface via the chemical ligation of the chosen targeting
peptide.44,47,49,52,53,56
Beyond that, the peptides can also be coupled to the block
copolymers prior to vesicle formation via mixing of the non-
functionalized polymer with a peptide-functionalized counter-
part that self-assemble together to form peptide-functionalized
polymersomes.46,48,50,51,54 Nevertheless, even if this approach
enables the simultaneous usage of different types of polymer,
e.g. by mixing a triblock co-polymer with a peptide-functionalized
diblock copolymer, several features like the use of polymers with
matching lengths of hydrophilic and hydrophobic parts is crucial
in order to achieve their co-self-assembly into polymersomes.48
It is also common to use a peptide-functionalized co-polymer with
a slightly longer hydrophilic block to enhance the exposure of the
peptide and potentiate the targeting/cell penetrating effect.54
Just like their shorter counterparts, proteins like transferrin
can be covalently attached to the surface of preformed poly-
mersomes for targeting purposes.53,57,58 For other applications
like sensors and regulating systems, the surface of polymer-
somes can be enriched with proteins via electrostatic interactions
prior to stable immobilization using photo-crosslinking.59 This
way, surface immobilized proteins that exhibit specific binding
properties are able to bind and release their compound of affinity
from the external environment, e.g. as anti-diabetes system:
Concanavalin A immobilized on the polymersome’s surface able
to bind glucose from the exterior. Surface immobilized fluores-
cently labelled proteins are also exploited as fluorescent tags to
monitor processes occurring within the membrane. For example
the membrane insertion of a non-fluorescent anchor of interest
can be detected by linking fluorescent eGFP to it.60
The surface of polymersomes has also been decorated
with nucleic acid based compounds for targeting applications.
Aptamers, which are DNA or RNA single strands with high
binding affinity to specific targets, are particularly interesting
for this goal. The 26-mer DNA aptamer AS1411 binds for
example selectively to nucleolin, a compound overexpressed
in certain types of cancer cells. Thus, the surface functionaliza-
tion of polymer vesicles with this aptamer can significantly
improve the endocytosis in these cancer cells lines.61,62 For
further applications, the specificity of the hybridization of
single-stranded DNA (ssDNA) towards their complementary
strands were exploited to selectively connect distinct polymer-
somes that are surface-functionalized with ssDNA. This approach
enables different spatial organizations of polymersomes into
clusters in order to mimic the interconnections between natural
cellular organelles.37
Among other possible applications like sensors, spatial
organisation or attachment, the main objective of surface
functionalisation of polymersomes is targeting, which explains
the recurrence of the selection of biomolecules (antibody,
peptides, DNA) able to direct the nanocompartments to the
location of choice. However, targeted polymersomes possess a
real interest only if they deliver a specific function, which is
usually obtained by encapsulation of compounds of interest or
potent biomolecules inside their cavity.
Biohybrid polymersomes with encapsulated payload
Polymer vesicles are appealing carriers for hydrophilic com-
pounds and biomolecules, especially for catalytic and sensitive
molecules like enzymes, as they offer a confined environment
inside their aqueous cavity and are thus able to protect the
payload from the external milieu.
Polymersomes encapsulating nucleic acid cargos offer
protection from nuclease degradation, which motivated recent
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work on their potency as non-viral, so potentially safer, gene
delivery systems.45,63,64 Plasmid DNA or siRNA can be
entrapped within the aqueous cavity of the vesicles via physical
encapsulation during polymersome formation.45,63 On one
hand, slightly positively charged polymers can support the
challenging encapsulation of large nucleic acids like plasmids
or genes by binding the negatively charged DNA via electro-
static forces.63,64 On the other hand, such interactions can
also destabilize the polymersome suspensions or prevent their
self-assembly. Thus, the length of the polymer block containing
protonatable groups as well as the pH have to be carefully
optimized to match the chosen nucleic acids with the self-
assembly conditions.63,64
The encapsulation of enzymes inside polymersomes’ cavity
to develop catalytic nanocompartments, also called nanoreactors,
able to produce or degrade compounds of interest have been
studied.65 Depending on the loaded enzymes, such biohybrid
systems aim to suit different applications. For example, polymer-
somes loaded with superoxide dismutase or haemoglobin act
as antioxidant nanocompartments as they enable the in situ
detoxification from reactive oxygen species (ROS).66,67 The
presence of two kinds of catalytic polymersomes working
in tandem (one encapsulating uricase and the other one horse-
radish peroxidase (HRP)) enables to cumulate the effects of
both catalytic nanocompartments to achieve simultaneous
detoxification and uric acid degradation for therapeutic appli-
cations (Fig. 4A).68 Additionally, such system, composed of two
kinds of catalytic polymersomes working in tandem, mimics
the communication within bioassemblies like cells and organelles
to investigate the effects of distance on the overall cascade
reaction efficiency (Fig. 4B).68 Interestingly, the ratio between
the mean intercompartment distance and the diameter of
the compartments is about 10, which reflects the order of
magnitude of the ratio between cell–cell communication
distance (for cells with 1 mm distance typical for autocrine
signaling). Besides therapeutic applications, catalytic polymer-
somes are also used as model for artificial organelles
(chloroplast,69 peroxisome70), building blocks of antimicrobial
surfaces71 or biosensors.72 The main role of the polymeric
nanocompartment is the segregation of the enzymes to protect
them from proteolytic degradation. However, the interaction
between the encapsulated enzymes and the external environment
is essential for the catalytic activity of the nanocompartment. The
majority of the polymersomes, assembled from PS–PIAT73 or
PGG74 for example, are inherently permeable to small molecules
and thus permit a supply in substrate for the encapsulated
enzyme and also the exit of a resulting product to the external
environment. On the opposite, polymersomes made of PDMS–
PMOXA block copolymers are impermeable to small molecules.
Selective permeability has been achieved via incorporation of
pores or channels in the polymeric membrane to establish a
molecular flow through the polymersomes (see next section).75
To study the permeabilization of the vesicles as well as the
diffusion of compounds through their polymeric membrane,
catalytic compartments encapsulating very stable enzymes like
HRP or glucose oxidase (GOx) were used as basic research, before
to aim at therapeutic applications. HRP and GOx benefit from the
well-established, accessible and convenient monitoring of their
reaction kinetics, which makes these enzymes suitable for
the development of artificial cells,76 models of molecular
crowding77 or enzyme positioning within the polymersomes.73
With the help of these stable model enzymes, it has been
demonstrated that the combined effect of enzyme confinement
coupled to a crowded milieu inside polymersomes affects the
enzyme kinetics by lowering the Michaelis–Menten constant
(Km) compared to non-encapsulated enzymes.
77 For example,
the Km value for non-encapsulated HRP (55  106 M)
decreases to 25  106 M when encapsulated in PMOXA–
PDMS–PMOXA polymersomes (Fig. 5). The co-encapsulation
of a substance simulating molecular crowding such as PEG
Fig. 4 (A) Scheme of the two catatylic compartments working in tandem. (B) Conversion of substrate Amplex Red by cascade reaction inside the
catalytic compartments in tandem representing the cascade reaction efficiency, at different mean intervesicles distances. Reprinted with permission from
ref. 68. Copyright (2018) American Chemical Society.
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together with HRP results in even lower Km (5  106 M)
(Fig. 5).77 This decrease of Michaelis–Menten constant for
encapsulated enzymes when co-encapsulated with their sub-
strates, highlights a greater enzyme–substrate affinity because
of the molecular confinement inside the compartment that
increases the collision frequencies between the reagents.77
Additionally, an increased viscosity inside the confined
environment via encapsulation of crowding agents to mimic
the viscosity of cells or organelles, also decreases the Km and
thus improves the enzyme activity.77
However, in a different system where enzymes are encapsulated
inside impermeable PMOXA–PDMS–PMOXA polymersomes, but
the substrate is not co-encapsulated but has to diffuse through
the pore to reach the enzymes, this diffusion effect is the limiting
factor of enzyme efficiency. In fact, if the substrate can easily
encounter the enzyme once in the compartment (low Km), the
slower efflux of substrate hinders the enzyme activity, according
to the decrease of catalytic efficiency (kcat/Km).
68 These parameters
(Km, kcat/Km, viscosity) are key factors to control to reach optimal
enzyme activity as desirable to develop efficient catalytic
nanocompartments.77 However, when such catalytic nano-
compartments are working in tandem and support cascade
reactions it is not anymore possible to use Michaelis–Menten
model to get information about the kinetic parameters.
From therapeutic compounds to catalytic biomolecules
(enzymes), encapsulated cargos often determine the application of
the biohybrid nanocompartment. However, the encapsulated pay-
loads can only fulfil their active/therapeutic role when in contact
with the external milieu, which is usually achieved via tuning of the
permeability/responsiveness of the polymeric membrane.
Biohybrid polymersomes with membrane functionalisation
Biomolecules containing a hydrophobic domain can be inserted
within the polymeric membrane to add new features to the bio-
hybrid nanocompartments such as stimuli-responsiveness.
In the case of the impermeable PDMS–PMOXA membrane,
the insertion of channel-forming antibiotic peptides like gra-
micidin leads to an ion-selective membrane permeability.36
The use of amphiphilic peptides can also be interesting to
achieve responsiveness. Such peptides self-assembling with
block-copolymers lead to polymer/peptide hybrid compartments,
so called peptiSomes, where the peptide part of the membrane
can be cleaved in the presence of proteinases. This allows the
proteolytic disruption of the compartments’ membranes and thus
the release of the payload.78 Some peptides also spontaneously
insert into the polymeric membrane of preformed polymersomes.
These peptides are generally derived from the transmembrane
domains of membrane proteins from viral, yeast or bacteriophage
sources.60 They can also originate from other natural proteins
like rabbit Cytochrome b5, or be artificial and engineered to
adopt an a-helical conformation.60 This approach permits to
avoid chemical ligation as their insertion appears to be a
concentration-dependent process governed by hydrophobic
driving forces. Furthermore, their anchoring properties permit
the functionalization of polymersomes with other molecules
without destabilizing or rupturing the polymersome membranes.60
More complex amino acid based biomolecules like proteins
have been used to constitute a major structural component
of biohybrid polymer vesicles: conjugates made of hydrophilic
human serum albumin and a hydrophobic polymer block self-
assembled into biodegradable protein–polymer vesicles that
show great potential as drug delivery vehicles.79 Another
amphiphilic BSA–polymer conjugate self-assembled into struc-
tures with tuneable and ‘’evolving’’ morphologies that changed
from sphere to worm and then to vesicles due to the increasing
molecular weight during polymerization. This process of
morphology change also enables the encapsulation of GFP, proving
potential for drug delivery.80 Asymmetric conjugates made of
ABC triblock copolymers containing either HRP or Myoglobin,
have been shown to form vesicles but also other nanoassemblies
like micelles or rods.81 However, only a few examples of such
protein–polymer conjugates have been reported to form desirable
nanoassemblies as the inherent complexity of these systems
impedes the control over their architecture. Moreover, membrane
proteins have been reconstituted in the polymeric membrane.
In case of impermeable polymersomes, the permeabilization that
is necessary for the confection of catalytic nanocompartments for
example can be achieved via the membrane insertion of protein
pores like Outer membrane protein F (OmpF). This porin has a
cut-off of 600 Da that permits the passage of small molecules into
and from the inner space of polymersomes while retaining bigger
encapsulated macromolecules like enzymes inside.77 OmpF can
also be chemically modified prior to the insertion to obtain pores
that open upon pH change82 or biovalves able to control the
opening and closing of the pore.83 Interestingly, the successful
incorporation of membrane proteins can be achieved even if the
polymeric membrane is thicker than biological lipid membranes
and thicker than the hydrophobic part of the protein, which
suggests a conformational adaptation between the polymer and
the protein.34 However, this phenomenon of adaption requires
specific properties of the polymeric membrane: high flexibility of
Fig. 5 Michaelis–Menten constant of HRP (free in solution and encapsu-
lated in polymersomes) in presence of different concentrations of PEG.
Km decreases with increasing concentrations of PEG. Reprinted with
permission from ref. 77. Copyright (2017) Wiley-VCH.
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block-copolymers is essential to achieve membrane fluidity that is
similar to natural phospholipidic bilayers.34 The hydrophobic
mismatch between the membrane thickness and the size of the
protein also influences the insertion process as it should range
from 3.5 to 5 times to achieve a successful protein reconstitution.
Finally, block-copolymers with high polydispersity index (PDI)
also favour protein insertion as they enhance the ability of the
polymer chains to adapt to the dimensions of protein.34 To go one
step further, the asymmetry of biological membranes has been
mimicked by the design of asymmetric ABC triblock copolymers,
which gives access to a preferential orientation of the inserted
protein.84 The orientation of membrane proteins is of great
interest to achieve a directional functionality,84 e.g. to control
the influx/outflux through polymersomes in case of active diffu-
sion of compounds via channel porins, or to control the exposi-
tion of the protein towards the cavity or the surface of vesicles.
Recent advances in polymer chemistry moved these syn-
thetic membranes closer to their biological inspiration, thus
allowing the successful insertion of several proteins like
a-hemolysin,85 Bacteriorhodopsin86 or AquaporinZ87 into polymeric
membranes. Nevertheless, the reconstitution of membrane proteins
in polymer membranes remains extremely complex as it requires a
high stability of the protein, adapted surfactant and pH conditions88
and strategies to deal with the hydrophobic size mismatch between
the protein and the synthetic membrane. The development of a
mathematical framework based on design of experiments (DoE) is a
particularly interesting approach to identify the requirements for a
successful reconstitution process of membrane proteins into
the membrane of polymersomes.88 This DoE method enables to
devise an experimental plan that samples a given parameter space
optimally, allowing a low number of experimental runs to detect
interactions and estimate factors’ effects. For example, the effects of
several factors (pH-values, detergent concentration and polymer/
protein ratio) on the biohybrid protein–polymersomes
characteristics (size, homogeneity, functionality) were identified
via the reconstitution of proton pump proteorhodopsin in polymer-
somes, using such an approach (Fig. 6).88
Besides proteins also carbohydrates can be inserted into the
membranes of polymersomes. Considering their variety of roles
in biological processes, notably in cell–cell and cell–matrix
communication, such biohybrids have been exploited for
applications like cell-surface recognition and cell signalling.
Only very few studies have been devoted to block-copolymers
containing sugar moieties with the ability to self-assemble into
vesicles.74,89,90 Notably, the development of enzyme responsive
vesicles involving the incorporation of enzyme-degradable
sugars within the block-copolymer: hyaluronic acid containing
block-copolymers have been used to set up hyaluronidase
responsive vesicles that were used for the detection of patho-
genic bacteria like Staphylococcus aureus that are secreting this
enzyme.91 In this sense, polymersomes with a glycosylated
surface can be considered as mimics of cells with their asso-
ciated pericellular matrix (glycocalix).90 Towards a similar goal,
so called glycosomes have been prepared via the co-self-assembly
of a phenylboronic acid-functionalized synthetic block-copolymer
with hydrophilic glycopolymers made of either galactoside or
glucoside.92 The assembly process is driven by the dynamic covalent
bond between the phenylboronic acid and sugars. Glycopolymer-
somes assembled from glycosylated block copolymers acted as
‘‘sugar sponges’’ to regulate the blood glucose level. The binding
of carbohydrate-binding proteins like lectin enabled the dynamic
sugar replacement between the free glucose of the external milieu
and the sugars exposed at the surface of vesicles.59 Additionally,
carbohydrate-conjugated polymers containing maltooligosaccharide
formed vesicles with interesting molecular-weight-dependent perme-
ability catalytic nanocompartments proposed in enzyme prodrug
therapy.74 The permeability coefficient is correlated to the partition
coefficient, and as small hydrophobic molecules have high partition
Fig. 6 (A) Interaction plot of the biohybrid proteorhodopsin/polymersome formation, showing the behavior (size, polydispersity index (PdI)) of formed
biohybrids toward changing conditions (pH, percentage of n-octyl-b-D-glucopyranoside (OG) surfactant, polymer/protein ratio (PPR). (B) Functionality of
the proteorhodopsin/polymersome hybrids: the proton gradient is dependent of the number of pumps reconstituted in the polymer membrane (as well
as their orientation and integrity). Highest proton-pumping activity should be found within the derived region yielding homogenous and large enough
vesicles: the modeled response surfaces of the pH gradient depending on factors influencing the formation of the hybrids like the two most influential
factors (pH, PPR), and third factor that is fixed at its central value (OG = 1.12%), shows that the formed pH gradient becomes larger at basic pH values and
higher PPR values. Reprinted from ref. 88. Creative Commons CC BY.
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coefficient, they are more likely to pass the membrane than larger
and more hydrophilic molecules.
The combination of block copolymers and phospholipids
has gained interest for the formation of hybrid vesicles with
membrane properties closer to biological ones. Phospholipid-
block copolymer conjugates were used for the preparation of
hybrid vesicles that were particularly studied for their cellular
interactions.93,94 They demonstrated the relevance of shear
stress in cell uptake and how shorter hydrophobic extensions
are enhancing their internalization by macrophages.93 Compared
to liposomes they also showed an enhanced lysosomal escape.95
Instead of using lipid–polymer conjugates, both types of macro-
molecules eventually also form hybrid vesicles if they are just
blended. The successful formation of such hybrid assemblies that
bring together the biocompatibility and softness of liposomes and
robustness and chemical versatility of polymersomes depends on
the correct choice of the amphiphilic building blocks. Molar
fraction, molecular weight and block size have to be optimized
in order to achieve a successful assembly. Block-copolymers that
closely match the dimensions of phospholipids have been shown
to favourably assemble into biohybrid vesicles.96–99 These hybrids
possess a great potential for drug delivery as the efficacy of
payload loading and release can be modulated by the polymer/
lipid ratio and the length of the diblock copolymer.99,100
In addition, such hybrid vesicles exhibit higher permeability
compared to polymersomes and liposomes, which has been
further enhanced by the insertion of ionophores or ion
channels.101 However, the biggest potential of hybrid lipid/
polymer vesicles has been shown for the reconstitution of
membrane proteins: they form a durable environment that
lowers the initial enzyme activity but enables a significant
extension of the functional lifetime of the protein compared
to its reconstitution in liposomes.102 Furthermore, the incor-
poration of lipids like phosphatidylcholine into polymeric
membranes can enhance the targeting properties of functiona-
lized vesicles. The insertion of a lipid as additional compound
into the membrane is diluting the density of polymer brushes
on the vesicle’s surface that are obstructing targeting ligands
due to steric effects.103 Such chimeric vesicles exhibit particu-
larly low toxicity in vitro and in vivo, especially at high ratio
of polymer and even at high concentrations of vesicles.104
The tunability and particular properties offered by such hybrid
systems is of great interest for the development of drug delivery
nanocarriers, imaging tools and catalytic nanocompartments.
The incorporation of biomolecules within the polymersome’s
membrane mainly enhances the tunability of the membrane,
especially permeability and responsiveness. However, further
investigations of the complex behaviour of the polymers with
biomolecules within these hybrid membranes are required, which
are often performed by the mean of GUVs considering the more
convenient characterization of their structure compared to their
nano-sized counterparts.99
Biohybrid PICsomes and layer-by-layer capsules
Other types of polymer-based nanocompartments have been
gaining interest as well: PICsomes and LbL capsules. Although
they have not been studied as extensively as polymersomes, a
small number of biohybrid PICsomes and LbL capsules has
been reported.
Surface-functionalization of PICsomes has been achieved
using peptides (cRGD) for neovascular targeting. Before their
functionalization, PICsomes were assembled and crosslinked
using EDC reaction to couple PEG-based block aniomers with
homo catiomers.105 This strategy of surface-functionalization,
rather than pre-functionalization of block-copolymers with
peptides before self-assembly, has been selected to avoid
peptide aggregation. The resulting peptide-functionalized
nanocompartments showed enhanced cell uptake and tumour
accumulation and aim for drug delivery and targeting applications.
The inner cavity of PICsomes has also been exploited to enclose
biomolecules: therapeutic-relevant L-asparaginase loaded into
PICsomes has been shown to retain the catalytic activity even
in vivo, which positions this system as an interesting applica-
tion of nanocompartments for cancer therapy.106
Finally, a nano-sized LbL capsule functionalized with a
peptide was used to target atherosclerotic plaques in vivo.107
However, these nanocompartments degraded in human plasma,
and their stabilization via deposition of poly-histidine on the core
particle before deposition of the polymers did not totally prevent
this phenomenon.107
One of the main differences between these nanocompart-
ments and polymersomes resides in the organization of their
shell/capsule, which resemble less to biological membranes.
Thus, the possibilities to mimic membrane-oriented biological
processes like membrane protein reconstitution are limited.
According to our knowledge, no examples of nano-sized PIC-
somes or LbL capsules with biomolecules directly embedded
within the shell/capsules have been reported. In this way,
polymersomes remain more polyvalent due to the tunability
of their inner cavity, surface, but also of their membrane using
biomolecules. However, innovations in polymer chemistry and
development of polymer–biomolecule conjugates as part of the
structure of these nanocompartments could replace membrane
proteins to achieve responsiveness and selective permeability.
Additionally, the lack of inherent robustness of PICsomes and
LbL capsules requires additional steps like crosslinking or
deposition of stabilization compounds, highlighting the need
for further research.
Micro-sized single compartment
biohybrid vesicles
To gain a comprehensive understanding of biohybrid membrane
properties and composition, GUVs within the micrometre range
are used. Using such large, cell sized vesicles, allows for the
visualization of the membrane structure or reactions that take
place within the inner cavity of the GUVs in real time, elucidating
whether domains are formed and providing information regarding
membrane fluidity, elasticity and integrity. These systems are
primarily used as artificial cells or cell models to study enzymatic
reactions within a controlled simplified surrounding that still
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retains selected characteristics of the cells. To create an artificial
cell the membrane composition can be adapted to contain lipid/
glycopolymer/polymer mixtures or biomolecule/polymer hybrids
and the inner cavity can be loaded with enzymes to study
membrane and crowding effects on biorelevant reactions.
Biohybrid GUVs: membrane properties, composition and
functionalization
Historically the first GUVs designed as artificial cells consisted
of a lipidic membrane, as these are considerably easier to form
since synthetic lipids will typically assemble into unilamellar
vesicles.19 However, larger lipid based GUVs are quite unstable
and cannot be stored for long periods of time, thus limiting
their applicability for biotechnological applications or as cell
models for reactions that have extended time periods.19
A solution consists in designing lipid–polymer hybrid mem-
branes that possess the strength and elasticity of the polymeric
membrane combined with the increased fluidity and thinness
of the lipid membrane (Fig. 7A).108,109 Obtaining hybrid mem-
branes that do indeed blend the best mechanical properties of
lipids and polymers is not trivial. It has been shown that mixing
PEO–PDMS–PEO triblock GUVs with increasing content of
lipids results in the formation of membranes with increased
stretching moduli however at the expense of toughness.110 The
mismatch between the length of the triblock copolymer and the
lipid as well as the stretched chain conformation of the polymer
within the membrane lead to destabilization of the membrane
at the lipid/polymer boundaries.110 Using triblock copolymers
with a higher molecular weight and longer hydrophobic block
can promote a U-shape conformation of the polymer within
the hybrid membrane.111 The entanglement induced by the
U-shape conformation results in hybrid GUVs with increased
stretching modulus and improved structural stability.111 Using
a PDMS–PEO diblock copolymers that self-assemble into a
bilayer does indeed overcome the limitations of the triblock
copolymer and when mixed with lipids, a hybrid membrane
with increased lysis strain and cohesive energy density, as
compared to the pure lipid GUVs, was obtained.112
Recently, it has been shown that mixing block copolymers
with lipids results in formation of lipid nano-domains, which
can grow into micrometre sized domains culminating in com-
plete phase separation.113 This effect depends on the mol% of
lipid within the final assembly, the main chain transition
temperature, the hydrophobic mismatch between the block
copolymer and the lipid and temperature (Fig. 7B).113,114
By controlling these parameters, domains with precise sizes
can be obtained. For example, low temperatures and mol% of
lipid within the assembly lead to small nano-meter sized
domains. Also, from a thermodynamic aspect, at low lipid
mol% entropy tends to dominate leading to a uniform distribu-
tion of the lipid within the membrane.115 Increasing the mol%
of incorporated lipids resulted in a growth of the domains
followed by complete phase separation at 50% molar lipid
compositions, budding and fission.113,114 At higher lipid frac-
tions, enthalpy dominates due to the hydrophobic mismatch
between the polymer and lipid, thus leading to phase separa-
tion and domain formation.115 The membrane properties are
also governed by the molar composition and is more fluid-like
at high polymer concentrations or more elastic-like at high
lipid composition.116 However, it is important to note that
formation of domains can lead to membranes with decreased
toughness with destabilization occurring at the lipid/polymer
boundaries.110,111
These types of hybrid compartments not only attempt to
amalgamate the top characteristics of polymers and lipids into
one cohesive unit, but can also be used to design asymmetric
membranes.17 Such membranes are obtained using a 2-step
procedure, where first the polymer or lipids are assembled into
a giant monolayered structure followed by addition of a second
monolayer of lipid or polymer, respectively. These membranes
will be used as tools for cell biomimicry to study the effects of
membrane asymmetry and heterogeneity found in natural cell
membranes.
While lipid/polymer hybrid membranes can be used as tools
to better understand the fluidity, elasticity, domain formation,
asymmetry and heterogeneity of natural membranes, a different
approach focuses on adding cell like recognition patterns to
artificial membranes. The cell membrane is covered by a glyco-
saminoglycan layer that can interact with multiple proteins
leading to activation of receptors, signalling pathways, as well
as pathogen infections.117 One approach to mimic the cell
membrane composition is by incorporating glycopolymers
within a polymeric membrane. This has been accomplished
Fig. 7 (A) Diffusion of fluorescently labelled proteins through lipid
membranes (squares) compared to triblock polymeric membranes (circles)
as a function of membrane thickness. Reprinted with permission from
ref. 34. Copyright (2015) American Chemical Society. (B) Overview of
polymer/lipid hybrid GUVs with different molar ratios highlighting domain
formation and phase separation. Reprinted with permission from ref. 114.
Copyright (2013) Elsevier.
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elegantly by coupling the hydrophobic PDMS blocks with a
hydrophilic heparin block118 or a glycopolymer block.119,120
In the case where heparin was used as a mimic for heparan
sulphate, small nanometre sized polymersomes121 or GUVs118
with exposed heparin on the surface were obtained. They were
shown to bind protamine, a heparin binding protein, thus these
GUVs can be used as a platform to study interactions of heparan
sulphate binding proteins with the cell surface. The interactions
between lectins and the cell surface glycan layer play key roles in
multiple biological processes including pathogen invasion.
To study these interactions biohybrid glycosylated polymers
have been used.119,120 These polymers were shown to selectively
interact with lectin functionalized beads or fimH positive E. coli,
thus mimicking natural cellular interactions. Along similar lines,
PICsomes were also tethered to carbohydrates to create a syn-
thetic glycosaminoglycan layer.122 In this case the aggregation
kinetics of PICsomes bound to lectins could be studied demon-
strating the availability and selectivity of multiple binding sites.
Biohybrid GUVs: membrane protein insertion
Membrane proteins have become important functional compo-
nents for biotechnical devices such as sensors, nanoreactors
and artificial cells as they enable a selective communication
between the inner cavity and the surroundings.123 One of the
first examples describing the insertion of membrane proteins
within a polymeric GUV was published in the early 2000s, where
3 different ionophores were used for selective or unselective
transport of calcium.124 Still to this day, formation of biohybrid
polymeric GUVs equipped with inserted proteins is considerably
more complex compared to polymersomes, as the decreased
membrane curvature of these larger GUVs, in some cases impedes
the functional insertion of membrane pores or peptide forming
pores.125 The strain of insertion can be overcome by using
PMOXA–PDMS–PMOXA block copolymers with tailored block
lengths, where the soft and flexible character of the PDMS
hydrophobic unit moulds to accommodate small hydrophobic
pores resulting in a stable assembly.36 By employing GUVs, the
fluidity of the membrane and diffusion of membrane pores
through the polymeric membrane has been measured by fluores-
cence correlation spectroscopy (FCS), revealing key molecular
parameters that play a role in polymeric biohybrid membrane
formation. One such factor that governs the functional insertion
of pores within a membrane is the block length of the block
copolymer. Increasing the block length, results in a thicker
membrane where the insertedmembrane pores exhibit a decrease
in lateral diffusion as they travel through the membrane.6
However, the flexible PDMS hydrophobic block enables the
contraction and compression of the membrane around the
inserted protein, to accommodate and surpass the hydrophobic
mismatch.34 The increased polydispersity of the block copolymer
also contributes to the polymer flexibility, where the shorter
polymeric chains within the membrane can readily adjust to
accommodate the inserted membrane protein. In a very recent
study it was also shown that insertion of melittin, a small pore
forming peptide, within a polymeric membrane can be facilitated
by adding the peptide during the early phases of the self-assembly
process.126 The interdependency of membrane curvature and
successful protein insertion was also explored and revealed that
increased membrane curvature promotes protein insertion, most
likely due to changes in packing as well as conformation of the
polymer when assembled within as vesicular structure as opposed
to a planar membrane.126 Using polymer–lipid hybrid membranes
that possess thin lipid domains could support improved
membrane protein insertion. In one example OmpF was indeed
successfully reconstituted in a polymer–lipid hybrid membrane.127
However, this field is still in its infancy with most of the research
focused on the membrane properties as opposed to membrane
protein insertion.
Biohybrid GUVs: encapsulating enzymes
To obtain giant catalytic compartments, biohybrid polymeric
membranes with inserted membrane pores can be used as an
approach to study catalytic reactions in real time. One such
system consists of incorporating OmpF within the membrane
of a PMOXA–PDMS–PMOXA triblock copolymer.128 Using this
type of catalytic compartment it was possible to study the
conversion of the substrate Amplex red to the fluorescent
substrate resorufin using confocal laser scanning microscopy.
Also due to the fact that GUVs are similarly sized to cells, it is
possible to analyse them via flow cytometry, thus obtaining
crucial information related to the entire sample population and
not only each GUV in particular. Giant PICsomes are also
exceptional candidate for the design of microreactors and
can be loaded with biologically relevant enzymes such as
metmyoglobin.129 The semipermeable nature of PICsome
together with the addition of a PEG biocompatible shell,
promotes the use of PICsomes as enzyme or drug carriers for
biomedical applications. Furthermore, cellular functions such
as cell secretion, can also be mimicked using GUVs by incor-
porating a cascade reaction that leads to the controlled rupture
of the polymeric membrane.130 To increase the encapsulation
efficiency and introduce a mixture of enzymes and substrates
within giants, microfluidics has been used to generate artificial
cells capable of expressing proteins in situ.131
As an alternative to encapsulating functional enzymes
or proteins, proteinosomes composed of a protein–polymer
membrane have been introduced.132 In this type of assembly
the membrane is composed of a protein inner leaflet, typically
bovine serum albumin functionalized with a pNIPAAm
polymer.133 The compartments assemble in water droplets
emulsified in a continuous oil phase forming micrometre sized
giants with an aqueous inner cavity. The inner cavity can be
loaded with enzymes, DNA or machinery needed for protein
expression to obtain biocompatible and functional micro-
reactors.133,134
Biohybrid LbL microreactors
The second most prevalent category of micrometre sized vesicles
are the giants fabricated through an LbL deposition of polyelec-
trolytes onto a core substrate.135,136 As these types of polymeric
LbL membranes are permeable towards small molecules, enzy-
matic reactions can take place within their inner cavity without
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the need for membrane inserted pores. Permeability of
these microreactors has been also tuned through the use of
temperature and/or pH responsive polymers such as poly-
(N-isopropylacrylamide) and polydiethylaminoethylmethacrylate,
respectively.135,137,138 Combining the stimuli responsiveness with
enzyme encapsulation, mostly revolving around GOx and catalase
as well as others,139 supports applications such as enzyme
replacement therapy, biocatalysis and biosensors.
Multicompartment biohybrid vesicles
The field of biological cell mimicry is further advanced by
the development of compartment-in-compartment biohybrid
vesicles. Such multicompartments are seen as a step forward
towards functional models for eukaryotic cells and their cellular
organelles, which are able to perform multiple chemically
incompatible enzymatic reactions simultaneously by separating
them in subcompartments. Besides the fundamental interest in
the creation of artificial cell mimics, compartmentalized vesicles
gained also increased attention for enzyme replacement therapy.
They could serve as biocompatible delivery vehicles preventing
administered enzymes from fast degradation in biological environ-
ments while offering at the same time space for additional cargos
and responsiveness for triggered catalytic activity or release, thus
mimicking the spatio-temporal control of cells over their metabolic
reactions.
Different multicompartment architectures
Multicompartment vesicles were pioneered with the development
of so called vesosomes where liposomes were encapsulated inside
bigger liposomes.140 This approach was rapidly transferred to
synthetic polymeric materials such as polymeric vesicles or LbL
capsules resulting in all possible combinations.141 They are
mainly classified by the bigger, outer compartment that is either
a LbL capsule, a polymeric vesicle or, as very recently realized, a
giant plasma membrane vesicle (GPMV).142
The encapsulation of the subcompartments, such as small
polymersomes, micelles or liposomes, inside polymeric vesicles
is usually achieved during their self-assembly by film rehydration,
in microfluidics or by double emulsions and emulsion centrifu-
gation methods, often resulting in mixtures of single and multi-
compartment structures that cannot be separated.
LbL multicompartments exist with either one smaller LbL
capsule as single subcompartment (shell-in-shell structure)143
or thousands of subcompartments that are deposited in a
controlled way onto the template during the preparation of
the micron sized outer capsule (Fig. 8).144 In this case, the
possible subcompartments comprise small LbL capsules,24
polymersomes,145 or liposomes,146 with the last ones being
used for the majority of all LbL biohybrid multicompartments.
The LbL approach allows the control over the spatial positioning
of the subcompartments. Depending on the polymers used for
the precursor or separation layer (Fig. 8), they either stay
attached to the inner walls of the LbL capsule or start to move
freely within the cavity after template removal.147 If only one
hemisphere of the template is accessible for the subunit
deposition, even Janus type multicompartments can be pre-
pared by the LbL approach.148
As for single compartments, the biological component can
be encapsulated as cargo inside the subunits or the lumen of
the main compartment, but it can be also found within or
outside of the membranes. Most of the biohybrid multi-
compartments are multifunctional systems that comprise different
classes of biomolecules in different places, e.g. enzymes inside the
subcompartment and channel proteins within the membranes or
lipids forming the subunits that encapsulate enzymes inside.
Biohybrid multicompartment LbL capsules
LbL assembled polymeric capsules are semipermeable by
nature, and thus able to keep larger (biomacro-)molecules or
subunits inside while allowing the diffusion of smaller ones,
i.e. substrates or analytes. For that reason, LbL capsules show
Fig. 8 (A) Schematic illustration of capsosome assembly. Reproduced
with permission from ref. 144. Copyright (2010) American Chemical
Society. (B) Capsosomes as intracellular microreactors loaded with GOx
and HRP for the enzymatic cascade conversion of b-D-glucose into
resorufin. (C) Differential interference contrast (DIC) and confocal laser
scanning (CLSM) microscopy images of macrophages with internalized
capsosomes showing the cascade’s red fluorescent end product resorufin
after 24 h. Control images in the absence of capsosomes are shown at the
bottom. (C) and (D) are reprinted with permission from ref. 154. Copyright
(2017) American Chemical Society.
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great potential for encapsulated enzymatic catalysis which was
demonstrated first by the enzymatic cascade between GOx and
peroxidase that have been separately encapsulated in an inner
and outer LbL compartment of a shell-in-shell structure.143
Their potential for applications in drug delivery is also related
to the selective degradation of LbL capsules upon different
chemical stimuli dependent on the crosslinking chemistry.
A polymer peptide conjugate as model vaccine was for instance
released from LbL subunits responsive to intracellular relevant
glutathione (GSH) concentrations.24
As already mentioned, most LbL derived multicompartments
are so-called capsosomes with liposomal subunits. Liposomes
offer protection for fragile encapsulated biomolecules or other
hydrophobic or hydrophilic substrates whereas the polymeric LbL
carrier capsule serves as structural scaffold. Cholesterol modified
polymer layers are necessary to immobilize the preformed lipo-
somes on the templates as pure electrostatic interactions are often
not enough to keep them in place when covered with the
subsequent polymer layer.146 Deposition in several layers allows
the delivery of high doses of encapsulated complementary cargos
in a controlled ratio within one carrier capsule.149
If capsosomes are used as microreactors, accessibility of the
enzyme inside the liposomal subunits is crucial and usually
achieved by permeabilizing them either with the help of
detergents146 or by an increase in temperature above the lipids’
melting temperature Tm. Hence, for medical applications, the
composition of the liposomal subunits is often tuned for a Tm
close to 37 1C. This concept allowed for instance the combi-
nation of enzyme therapy (the continuous production of GSH
as antioxidant) with triggered drug release (here a small oligo-
peptide cleaved from its linker by GSH) in the same system.150
Cascade or parallel reactions using up to three different
enzymes were advanced using PDA based capsosomes (e.g.
uricase, HRP and ascorbate oxidase)25 which were later further
optimized for the encapsulation of medically relevant enzymes
(e.g. for the treatment of phenylketonuria151 or melanoma152).
As a proof of concept, the enzymatic activity of such extra-
cellular microreactors was shown in microfluidic setups
mimicking the dynamic conditions of tumor or intestine
tissues.151,152
Another step forward to the application of capsosomes in
enzyme replacement therapy was achieved with the demonstra-
tion of intracellular activity after supporting cell uptake with
PEG surface grafting and RGD functionalization.153 Intracellular
activity in macrophages could also be shown for two enzymes
encapsulated in distinct liposomal subunits working as cascade154
or in parallel.155 Fluorescent Au nanoclusters were additionally
incorporated into the systems to monitor cellular uptake.
Despite this encouraging progress some challenges remain,
such as a prolonged stability of the liposomal subcompartments
to ensure a sustained activity of the encapsulated enzyme as well
as an improved encapsulation efficiency. Replacement of the
liposomal subcompartments with polymersomes offers a possibi-
lity to address these challenges. However, examples for polymer-
some subunits in LbL capsules remain scarce. In one of the rare
examples, plasmid DNA has been released from polymersome
subunits by a double switch in pH.145
Biohybrid multicompartment polymeric vesicles
Multicompartment vesicles for the encapsulation of biomacro-
molecules have also been prepared solely on the basis of
polymersomes. As proof of principle, fluorescent proteins
were encapsulated inside the distinct compartments of a
polymersome-in-polymersome structure with 45% of the poly-
mersomes being multicompartments.156 With the introduction
of the channel protein OmpF into the membrane of the inner
Fig. 9 (A) Schematic representation of the modular multicompartment system able to mimic a cellular signal transduction strategy. (B) DTT triggered
gramicidin gA ion channel recruitment from subcompartments to the polymer membrane visualized by activation of a sodium ion sensitive dye (green
fluorescence in CLSM images) either by gA mediated Na+ efflux (upper part) or gA mediated Na+ influx (lower part). Reprinted with permission from
ref. 118. Copyright (2019) Wiley-VCH.
Perspective PCCP
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
pr
il 
20
20
. D
ow
nl
oa
de
d 
on
 6
/2
3/
20
20
 1
0:
52
:0
9 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©the Owner Societies 2020 Phys. Chem. Chem. Phys., 2020, 22, 11197--11218 | 11213
polymersome, a cascade reaction was enabled between HRP in
the subcompartment and GOx in the lumen of the semiperme-
able outer polymersome, thus advancing this system to a cell
mimic.76 Later, a cofactor dependent three enzyme cascade was
realized inside a GUV encapsulating one enzyme, the substrates
and a cofactor in its lumen and two other enzymes inside
its semipermeable polymersome subcompartments using an
emulsion-centrifugation process.7
Recently, a multicompartmentalized GUV containing poly-
mersomes, micelles and reduction sensitive nanoparticles as
three different subcompartments was reported for mimicking a
cellular signal transduction strategy (Fig. 9).118 First, Heparin
was used as receptor like surface modification and allowed the
targeted interaction with protamine. Second, the reaction of a
hydrophobic enzyme, immobilized within the membrane of the
GUVs, was started on demand by releasing its substrate from
the reduction sensitive nanoparticles. In a third scenario,
the GUVs were selectively permeabilized for sodium ions by
directing the peptide ion channel gramicidin A into the GUV
membrane after its stimuli responsive release from the encap-
sulated nanoparticles.
Beyond polymersomes also liposomes serve as subcompart-
ments inside synthetic GUVs. The tunability of their melting
temperature by changing the lipid composition was exploited
for a temperature triggered sequential release of dyes from
liposomal subcompartments inside a GUV with the future aim
of starting cascade reactions on demand inside the polymer-
some as microreactor.18
An early example for a multicompartment vesicle showed as
well the inverse configuration by encapsulating polymersomes
inside a bigger liposome without providing any specific
functionality.157 In contrast, polymersomes were introduced
very recently as subcompartments into giant plasma membrane
vesicles (GPMVs) to form molecular factories.142 GPMVs are
giant vesicles directly isolated from cells. As such they provide the
lipid and protein complexity of intact cell plasma membranes
together with the cytoplasm inside. The reported molecular
factories are the first example of functional artificial cells with
the outer membrane complexity of a cell, internal cytoplasm
and synthetic artificial organelles (enzyme filled polymersomes
equipped with channel porins) that are functional even under
in vivo conditions in a zebrafish vertebrate animal model
without showing toxicity.
Conclusion and perspectives
The examples given in this review demonstrate the great progress
in the field of micro- or nano-sized biohybrid compartments.
During the past decade, these systems advanced from simple
polymeric vesicles encapsulating simply dyes as proof of principle
or just one type of biomolecule to complex multifunctional
and even multicompartmentalized biohybrid materials ready
for medical applications. Most systems exploit the chemical
robustness of synthetic polymers for protection of their delicate
biomolecular cargos and use the polymers’ chemical tunability
to adapt their properties for the desired application and
functionalization. A great variety of techniques are nowadays
available for vesicle or polymeric capsule production at the
micro- and nanoscale and the controlled incorporation of
biomolecular cargos.
It was shown for all classes of biomolecules that their
intrinsic functionality can be preserved and specifically exploited
in such biohybrid compartments: transmembrane proteins intro-
duce selective permeability to polymeric vesicles, lipids tune their
biophysical properties for improved biocompatibility, peptide
functionalization allows selective targeting while encapsulation
of enzymes supports spatially confined catalytic activity.
Research in such biohybrid compartments is motivated on
one hand by direct applications in drug delivery of e.g. encap-
sulated proteins, nucleic acids or hydrophobic molecules
entrapped within the membrane. On the other hand, it is
driven by the fundamental interest in advancing biohybrids
to artificial cell mimics. Several principles like the compart-
mentalized structure, confined enzymatic catalysis or simple
cellular signal transduction and biological permeabilization
strategies have been successfully implemented in biohybrid
compartments.
However, selective permeabilization and responsiveness
to specific stimuli are still under intense investigation as for
instance the reconstitution of membrane proteins is not fully
understood and cannot be generally achieved yet. Further
studies of the required membrane properties, with the help
of lipid/polymer biohybrid membranes, will promote that field.
Furthermore, improvements in the encapsulation efficiency of
biomacromolecular cargos inside the polymeric compartments
would have a great impact on drug delivery applications as well
as on nano/microreactors exploiting the catalytic activity of
enzymes. Similar strategies are also required for the controlled
assembly of multicompartmentalized biohybrids if different
types of subunits in precise amounts and ratios should be
used. Finally, such complex biohybrid systems still lack exten-
sive investigations of their fate in contact with a real biological
environment, such as living tissues or organisms. In this
respect, also a tuneable biodegradability would be favourable.
All in all, there is still plenty of research needed before fully
functional cell models or complex artificial organelles with
therapeutic relevance can be realized.
Abbreviations
Polymers
BA Butyl acrylate
CMA 4-Methyl-[7-methacryloyl) oxyethyloxy] coumarin
DEA 2-(Diethylamino)ethyl methacrylate
DEGMA (Diethylene glycol) methyl ether methacrylate
DMAEMA Dimethylaminoethyl acrylate
PDTC/DTC Poly(2,2-dimethyltrimethylene carbonate)
P(ASP) Poly(a,b-aspartic acid)
P(Asp-AP) Poly[(5-aminopentyl)-a,b-aspartamide]
PAA Poly(acrylic acid)
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PAH Polyallylamine
PB Poly(butadiene)
PBMA Poly(butyl methacrylate)
PCL Poly(caprolactone)
PCMA Poly(2-cinnamoylethyl methacrylate)
PDPA Poly(2-(diisopropylamino)ethyl methacrylate)
PDEAEMA Poly(2-(diethylamino)ethyl methacrylate)
PDMS Poly(dimethylsiloxane)
PCL Poly(caprolactone)
PEP Isopropyl ethylene phosphate
PEG/PEO Poly(ethylene glycol)/poly(ethylene oxide)
PEOGA Poly(oligoethylene glycol acrylate)
PGA Poly(glutamic acid)
PGG Poly(L-g-glutamyl-glutamine)
PHPMA Poly(2-hydroxypropyl methacrylate)
PI Poly(isoprene)
PIAT Polyisocyanoalanine(2-thiophene-3-yl-
ethyl)amide
PLA Polylactic acid
PLG Poly(L-glutamate)
PLGA Poly(lactic-glycolic acid)
PLL Poly(L-lysine)
PMA Poly(methacrylic acid)
PMOXA Poly(2-methyloxazoline)
PMPC Poly(2-(methacryloyloxy)ethyl
phosphorylcholine)
PNIPAM Poly(N-isopropylacrylamide)
POEGMA Poly[2-(2-methoxyethoxy)ethyl methacrylate-co-
oligo (ethylene glycol)methyl ether methacrylate]
PS Polystyrene
PSS Poly(styrene-4-sulfonic acid)
PTMC/TMC Poly(trimethylene carbonate)
PVP Poly(vinylpyrrolidone)
PVPON poly(N-vinyl pyrrolidone)
Lipids
DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine
DOPS 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine
DMPC 1,2-Dimyristoyl-sn-glycero-3-phosphocholine
DPPC 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
DPPS 1,2-Dipalmitoyl-sn-glycero-3-phosphoserine
HSPC Hydrogenated soybean phosphatidylcholine
PC Phosphatidylcholines
PE Phosphatidylethanolamine
POPC 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
Proteins and Peptides
ADH Alcohol dehydrogenase
Alc Alcalase
ALP Alkaline phosphatase
ApoE Apolipoprotein E
Aqp Z Aquaporin Z
ASNase Asparaginase
BR Bacteriorhodopsin
BSA Bovine serum albumin
CalB Lipase B from Candida antarctica
Cat Catalase
cRGD CyclicRGD
cytC Cytochrome c
gA Gramicidin A
GALA Glutamic acid-alanine-leucine-alanine
GFP Green fluorescent protein
GOx Glucose oxidase
GR Glutathione reductase
HAS Human serum albumin
Hb Hemoglobin
HRP Horseradish peroxidase
iRGD InternalizingRGD
LPO Lactoperoxidase
LPL Lipoprotein lipase
Mb Myoglobin
NLS Nuclear localization sequence
OmpF Outer membrane protein F
PAL Phenylalanine ammonia lyase
PAMO Phenylacetone Monooxygenase
PGM Phosphoglucomutase
POD Peroxidase
RNApol RNA polymerase
SOD Superoxide dismutase
TRP Trypsin
TYR Tyrosinase
a-HL a-Haemolysin
b-gal b-Galactosidase
b-lac b-Lactamase
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